Showing results (1-10 of 125) with videos related to

Sort By:
Pageof 13
Kidney & Blood Pressure Research|July 1, 2010
Treatment of Hemodialysis-Associated Adynamic Bone Disease with Teriparatide (PTH1-34): A Pilot StudyDaniel Cejka, Katharina Kodras, Till Bader, et al.
Bone|April 9, 2014
Inverse association between bone microarchitecture assessed by HR-pQCT and coronary artery calcification in patients with end-stage renal diseaseDaniel Cejka, Michael Weber, Danielle Diarra, et al.
Blood Purification|September 18, 2014
Sclerostin declines during hemodialysis and appears in DialysateBernhard O Bielesz, Till Hempfing, Heidi Kieweg, et al.
The Journal of Clinical Endocrinology and Metabolism|November 5, 2013
Renal elimination of sclerostin increases with declining kidney functionDaniel Cejka, Rodrig Marculescu, Nicolas Kozakowski, et al.
Metabolites|November 25, 2021
Cardiovascular Safety of Anti-Sclerostin Therapy in Chronic Kidney DiseaseDaniel Cejka
Wiener Medizinische Wochenschrift (1946)|May 10, 2013
Renale osteodystrophieDaniel Cejka
Clinical Journal of the American Society of Nephrology : CJASN|December 18, 2010
Sclerostin and Dickkopf-1 in renal osteodystrophyDaniel Cejka, Johann Herberth, Adam J Branscum, et al.
Clinical Journal of the American Society of Nephrology : CJASN|July 9, 2011
Bone microarchitecture in hemodialysis patients assessed by HR-pQCTDaniel Cejka, Janina M Patsch, Michael Weber, et al.
Clinical Biochemistry|June 24, 2014
Correlations and time course of FGF23 and markers of bone metabolism in maintenance hemodialysis patientsBernhard O Bielesz, Manfred Hecking, Max Plischke, et al.
Current Opinion in Nephrology and Hypertension|April 16, 2019
An overview of the mechanisms in vascular calcification during chronic kidney diseaseJakob Voelkl, Daniel Cejka, Ioana Alesutan
Pageof 13